INTRODUCTION: This paper reports the synthesis and labeling of (18)F alanine derivatives. We also investigate their biological characteristics as potential tumor imaging agents mediated by alanine-serine-cysteine preferring (ASC) transporter system. METHODS: Three new (18)F alanine derivatives were prepared from corresponding tosylate-precursors through a two-step labeling reaction. In vitro uptake studies to evaluate and to compare these three analogs were carried out in 9L glioma and PC-3 prostate cancer cell lines. Potential transport mechanisms, protein incorporation and stability of 3-(1-[(18)F]fluoromethyl)-L-alanine (L-[(18)F]FMA) were investigated in 9L glioma cells. Its biodistribution was determined in a rat-bearing 9L tumor model. PET imaging studies were performed on rat bearing 9L glioma tumors and transgenic mouse carrying spontaneous generated M/tomND tumor (mammary gland adenocarcinoma). RESULTS: New (18)F alanine derivatives were prepared with 7%-34% uncorrected radiochemical yields, excellent enantiomeric purity (>99%) and good radiochemical purity (>99%). In vitro uptake of the L-[(18)F]FMA in 9L glioma and PC-3 prostate cancer cells was higher than that observed for the other two alanine derivatives and [(18)F]FDG in the first 1h. Inhibition of cell uptake studies suggested that L-[(18)F]FMA uptake in 9L glioma was predominantly via transport system ASC. After entering into cells, L-[(18)F]FMA remained stable and was not incorporated into protein within 2h. In vivo biodistribution studies demonstrated that L-[(18)F]FMA had relatively high uptake in liver and kidney. Tumor uptake was fast, reaching a maximum within 30 min. The tumor-to-muscle, tumor-to-blood and tumor-to-brain ratios at 60 min post injection were 2.2, 1.9 and 3.0, respectively. In PET imaging studies, tumors were visualized with L-[(18)F]FMA in both 9L rat and transgenic mouse. CONCLUSION: L-[(18)F]FMA showed promising properties as a PET imaging agent for up-regulated ASC transporter associated with tumor proliferation.
INTRODUCTION: This paper reports the synthesis and labeling of (18)F alanine derivatives. We also investigate their biological characteristics as potential tumor imaging agents mediated by alanine-serine-cysteine preferring (ASC) transporter system. METHODS: Three new (18)F alanine derivatives were prepared from corresponding tosylate-precursors through a two-step labeling reaction. In vitro uptake studies to evaluate and to compare these three analogs were carried out in 9L glioma and PC-3prostate cancer cell lines. Potential transport mechanisms, protein incorporation and stability of 3-(1-[(18)F]fluoromethyl)-L-alanine (L-[(18)F]FMA) were investigated in 9L glioma cells. Its biodistribution was determined in a rat-bearing 9L tumor model. PET imaging studies were performed on rat bearing 9L glioma tumors and transgenicmouse carrying spontaneous generated M/tomND tumor (mammary gland adenocarcinoma). RESULTS: New (18)F alanine derivatives were prepared with 7%-34% uncorrected radiochemical yields, excellent enantiomeric purity (>99%) and good radiochemical purity (>99%). In vitro uptake of the L-[(18)F]FMA in 9L glioma and PC-3prostate cancer cells was higher than that observed for the other two alanine derivatives and [(18)F]FDG in the first 1h. Inhibition of cell uptake studies suggested that L-[(18)F]FMA uptake in 9L glioma was predominantly via transport system ASC. After entering into cells, L-[(18)F]FMA remained stable and was not incorporated into protein within 2h. In vivo biodistribution studies demonstrated that L-[(18)F]FMA had relatively high uptake in liver and kidney. Tumor uptake was fast, reaching a maximum within 30 min. The tumor-to-muscle, tumor-to-blood and tumor-to-brain ratios at 60 min post injection were 2.2, 1.9 and 3.0, respectively. In PET imaging studies, tumors were visualized with L-[(18)F]FMA in both 9L rat and transgenicmouse. CONCLUSION:L-[(18)F]FMA showed promising properties as a PET imaging agent for up-regulated ASC transporter associated with tumor proliferation.
Authors: Weiping Yu; Larry Williams; Vernon M Camp; Jeffrey J Olson; Mark M Goodman Journal: Bioorg Med Chem Lett Date: 2010-02-14 Impact factor: 2.823
Authors: Wenchao Qu; Zhihao Zha; Karl Ploessl; Brian P Lieberman; Lin Zhu; David R Wise; Craig B Thompson; Hank F Kung Journal: J Am Chem Soc Date: 2010-12-29 Impact factor: 15.419
Authors: Barbara J Fueger; Johannes Czernin; Timothy Cloughesy; Daniel H Silverman; Cheri L Geist; Martin A Walter; Christiaan Schiepers; Phioanh Nghiemphu; Albert Lai; Michael E Phelps; Wei Chen Journal: J Nucl Med Date: 2010-09-16 Impact factor: 10.057
Authors: Kiel D Neumann; Javier E Villanueva-Meyer; Christopher A Mutch; Robert R Flavell; Joseph E Blecha; Tiffany Kwak; Renuka Sriram; Henry F VanBrocklin; Oren S Rosenberg; Michael A Ohliger; David M Wilson Journal: Sci Rep Date: 2017-08-11 Impact factor: 4.379
Authors: Matthew F L Parker; Justin M Luu; Brailee Schulte; Tony L Huynh; Megan N Stewart; Renuka Sriram; Michelle A Yu; Salma Jivan; Peter J Turnbaugh; Robert R Flavell; Oren S Rosenberg; Michael A Ohliger; David M Wilson Journal: ACS Cent Sci Date: 2020-02-04 Impact factor: 14.553